Intratumoral Concentrations and Effects of Orally Administered Micellar Curcuminoids in Glioblastoma Patients

References

• Stupp R, Hegi ME, Gilbert MR, and Chakravarti A: Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25, 4127–4136, 2007. doi: 10.1200/JCO.2007.11.8554
   PubMed Web of Science ®Google Scholar
• Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, et al.: A urokinase receptor-bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Res 75, 394–404, 2015. doi: 10.1158/0008-5472.CAN-14-2004
   PubMed Web of Science ®Google Scholar
• Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, et al.: Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343, 72–76, 2014. doi: 10.1126/science.1241328
   PubMed Web of Science ®Google Scholar
• Reardon DA, and Wen PY: Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol 12, 69–70, 2015. doi: 10.1038/nrclinonc.2014.223.
   PubMed Web of Science ®Google Scholar
• Ozawa T, and Holland EC: Rethinking glioma treatment strategy. Oncotarget 5, 9532–9533, 2014.
   PubMed Web of Science ®Google Scholar
• Lopez-Lazaro M: Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 52 Suppl 1, S103–S127, 2008.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration: GRAS Notice No. 460. http://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices
   Google Scholar
• Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21, 2895–2900, 2001.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, and Shishodia S: Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann N Y Acad Sci 1030, 434–441, 2004.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, et al.: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11, 7490–7498, 2005.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, et al.: Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 69, 195–206, 2006.
   PubMed Web of Science ®Google Scholar
• Anto RJ, Mukhopadhyay A, Denning K, and Aggarwal BB: Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 23, 143–150, 2002.
   PubMed Web of Science ®Google Scholar
• Senft C, Polacin M, Priester M, Seifert V, Kogel D, et al.: The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC Cancer 10, 491, 2010. doi: 10.1186/1471-2407-10-491
   PubMed Web of Science ®Google Scholar
• Weissenberger J, Priester M, Bernreuther C, Rakel S, Glatzel M, et al.: Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1,2/STAT3 signaling pathway. Clin Cancer Res 16, 5781–5795, 2010. doi: 10.1158/1078-0432.CCR-10-0446
   PubMed Web of Science ®Google Scholar
• Schiborr C, Eckert GP, Rimbach G, and Frank J: A validated method for the quantification of curcumin in plasma and brain tissue by fast narrow-bore high-performance liquid chromatography with fluorescence detection. Anal Bioanal Chem 397, 1917–1925, 2010. doi: 10.1007/s00216-010-3719-3
   PubMed Web of Science ®Google Scholar
• Kocher A, Hagl S, Schiborr C, Eckert GP, and Frank J: Concentrations of total curcuminoids in plasma, but not liver and kidney, are higher in 18- than in 3-months old mice. NFS J 1, 3–8, 2015. doi: http://dx.doi.org/10.1016/j.nfs.2015.03.002
   Google Scholar
• Teiten MH, Dicato M, and Diederich M: Hybrid curcumin compounds: a new strategy for cancer treatment. Molecules 19, 20839–20863, 2014. doi: 10.3390/molecules191220839
   PubMed Web of Science ®Google Scholar
• Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, et al.: The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res 58, 516–527, 2014. doi: 10.1002/mnfr.201300724
   PubMed Web of Science ®Google Scholar
• Kocher A, Schiborr C, Behnam D, and Frank J: The oral bioavailability of curcuminoids in healthy humans is markedly enhanced by micellar solubilisation but not further improved by simultaneous ingestion of sesamin, ferulic acid, naringenin and xanthohumol. J Func Foods 14, 183–191, 2015. doi: http://dx.doi.org/10.1016/j.jff.2015.01.045
   Web of Science ®Google Scholar
• Glunde K, Jie C, and Bhujwalla ZM: Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia 8, 758–771, 2006. doi: 10.1593/neo.06187
   PubMed Web of Science ®Google Scholar
• Sterin M, Cohen JS, Mardor Y, Berman E, and Ringel I: Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study. Cancer Res 61, 7536–7543, 2001
   PubMed Web of Science ®Google Scholar
• Mirbahai L, Wilson M, Shaw CS, McConville C, Malcomson RD, et al.: 1H magnetic resonance spectroscopy metabolites as biomarkers for cell cycle arrest and cell death in rat glioma cells. Int J Biochem Cell Biol 43, 990–1001, 2011. doi: 10.1016/j.biocel.2010.07.002
   PubMed Web of Science ®Google Scholar
• Podo F: Tumour phospholipid metabolism. NMR Biomed 12, 413–439, 1999.
   PubMed Web of Science ®Google Scholar
• Hattingen E, Jurcoane A, Bahr O, Rieger J, Magerkurth J, et al.: Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro Oncol 13, 1349–1363, 2011. doi: 10.1093/neuonc/nor132
   PubMed Web of Science ®Google Scholar
• Hattingen E, Bahr O, Rieger J, Blasel S, Steinbach J, et al.: Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy. PLoS One 8, e56439, 2013. doi: 10.1371/journal.pone.0056439.
   PubMed Web of Science ®Google Scholar
• Heath DD, Pruitt MA, Brenner DE, and Rock CL: Curcumin in plasma and urine: quantitation by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 783, 287–295, 2003.
   PubMed Web of Science ®Google Scholar
• Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, et al.: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14, 4491–4499, 2008.
   PubMed Web of Science ®Google Scholar
• Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, et al.: Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem 58, 2095–2099.
   PubMed Web of Science ®Google Scholar
• Thayyullathil F, Rahman A, Pallichankandy S, Patel M, and Galadari S: ROS-dependent prostate apoptosis response-4 (Par-4) up-regulation and ceramide generation are the prime signaling events associated with curcumin-induced autophagic cell death in human malignant glioma. FEBS Open Bio 4, 763–776, 2014. doi: 10.1016/j.fob.2014.08.005
   PubMed Web of Science ®Google Scholar
• Kumar A, Ahuja A, Ali J, and Baboota S: Curcumin-loaded lipid nanocarrier for improving bioavailability, stability and cytotoxicity against malignant glioma cells. Drug Del, 23, 214-219, 2016. doi: 10.3109/10717544.2014.909906
   Web of Science ®Google Scholar
• Tagami T, Imao Y, Ito S, Nakada A, and Ozeki T: Simple and effective preparation of nano-pulverized curcumin by femtosecond laser ablation and the cytotoxic effect on C6 rat glioma cells in vitro. Int J Pharm 468, 91–96, 2014. doi: 10.1016/j.ijpharm.2014.04.013
   PubMed Web of Science ®Google Scholar
• Du WZ, Feng Y, Wang XF, Piao XY, Cui YQ, et al.: Curcumin suppresses malignant glioma cells growth and induces apoptosis by inhibition of SHH/GLI1 signaling pathway in vitro and vivo. CNS Neurosci Ther 19, 926–936, 2013. doi: 10.1111/cns.12163
   PubMed Web of Science ®Google Scholar
• Zanotto-Filho A, Coradini K, Braganhol E, Schroder R, de Oliveira CM, et al.: Curcumin-loaded lipid-core nanocapsules as a strategy to improve pharmacological efficacy of curcumin in glioma treatment. Eur J Pharm Biopharm 83, 156–167, 2013. doi: 10.1016/j.ejpb.2012.10.019
   PubMed Web of Science ®Google Scholar
• Zhuang W, Long L, Zheng B, Ji W, Yang N, et al.: Curcumin promotes differentiation of glioma-initiating cells by inducing autophagy. Cancer Sci 103, 684–690, 2012. doi: 10.1111/j.1349-7006.2011.02198.x
   PubMed Web of Science ®Google Scholar
• Guo G, Fu S, Zhou L, Liang H, Fan M, et al.: Preparation of curcumin loaded poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) nanofibers and their in vitro antitumor activity against Glioma 9L cells. Nanoscale 3, 3825–3832, 2011. doi: 10.1039/c1nr10484e
   PubMed Web of Science ®Google Scholar
• Shao J, Zheng D, Jiang Z, Xu H, Hu Y, et al.: Curcumin delivery by methoxy polyethylene glycol-poly(caprolactone) nanoparticles inhibits the growth of C6 glioma cells. Acta Biochim Biophys Sin (Shanghai) 43, 267–274, 2011. doi: 10.1093/abbs/gmr011
   PubMed Web of Science ®Google Scholar